NCT02264678 2026-02-20
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
AstraZeneca
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT02734004 2026-01-29
MEDIOLA
AstraZeneca
Phase 1/2 Active not recruiting
NCT03983954 2025-11-28
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
Phase 1 Active not recruiting
NCT03737643 2025-01-29
DUO-O
AstraZeneca
Phase 3 Active not recruiting
NCT03323398 2024-07-31
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
ModernaTX, Inc.
Phase 1/2 Terminated